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Background: LINE-1 (L1) retrotransposons are common occupants of mammalian genomes representing about a
fifth of the genetic content. Ongoing L1 retrotransposition in the germ line and somatic tissues has contributed to
structural genomic variations and disease-causing mutations in the human genome. L1 mobilization relies on the
function of two, self-encoded proteins, ORF1 and ORF2. The ORF2 protein contains two characterized domains:
endonuclease and reverse transcriptase.
Results: Using a bacterially purified endonuclease domain of the human L1 ORF2 protein, we have generated a
monoclonal antibody specific to the human ORF2 protein. We determined that the epitope recognized by this
monoclonal antibody includes amino acid 205, which is required for the function of the L1 ORF2 protein endonuclease.
Using an in vitro L1 cleavage assay, we demonstrate that the monoclonal anti-ORF2 protein antibody partially inhibits
L1 endonuclease activity without having any effect on the in vitro activity of the human AP endonuclease.
Conclusions: Overall, our data demonstrate that this anti-ORF2 protein monoclonal antibody is a useful tool for
human L1-related studies and that it provides a rationale for the development of antibody-based inhibitors of
L1-induced damage.
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Long interspersed element-1 (L1) is an autonomous
non-long terminal repeat retrotransposon that has para-
sitized the human genome for millions of years. L1 has
shaped the evolution of the human genome through a
copy-and-paste mobilization of itself [1], as well as the
short interspersed element (SINE) Alu [2], SINE-VNTR-
Alu elements (SVA) [3], and processed cellular transcripts
[4]. Functional full-length L1 transcripts contain two open
reading frames (ORFs) encoding ORF1 and ORF2 proteins
(ORF1p and ORF2p, respectively) (Figure 1A). These
L1 proteins exhibit cis-preference for their encoding L1
mRNA [5-7] and are utilized in trans by the Alu and* Correspondence: vperepe@tulane.edu
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unless otherwise stated.SVA elements [2,3,8]. L1, Alu, and SVA form ribonu-
cleoprotein (RNP) particles which reach the nucleus to
complete their replication cycles by integrating in the
host genome via a process of target-primed reverse
transcription [9,10]. This copy-and-paste process has
produced approximately 500,000 L1 loci, accounting for
about 17% of the human genome, and over 1,000,000
copies of Alu, which comprise about 11% of our genome
[11]. The majority of the L1 loci are 5′ truncated with
about 80 to 100 full-length L1 copies demonstrated to be
retrotranspositionally active [12-16].
L1 proteins are produced from the full-length L1 mRNA
with significantly different efficiencies, mostly owing to
the unconventional translation from the bicistronic L1
mRNA [17-20] (Figure 1A). Detection of both L1-encoded
proteins is important in understanding L1 biology since
they play critical, but different roles in the L1 replication
cycle. The human ORF2p is a 149 kilodalton (kDa) proteintral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Analysis of bacterially purified human endonuclease. (A) Schematic of a full-length L1, which contains a 5′ untranslated region
(UTR) followed by an ORF1 sequence, an intergenic region, an ORF2 sequence, and a 3′ UTR. The EN region of the ORF2 sequence subcloned to
generate the purified ORF2p endonuclease (EN, 1-239aa) is indicated with a dashed box. (B) (Left panel) Coomassie stain of SDS-PAGE gel.
Ladder (L), clarified lysate from bacteria expressing ORF2p endonuclease (CL), and final purified elution (PE) are shown; 500 ng of protein was
loaded in each lane. (Middle panel) Western blot analysis of 500 ng of CL and PE with HIS-tag specific antibodies. The ORF2p endonuclease used
in this study has a HIS-tag fused to its N-terminus (expected size of the His EN protein is 29 kilodaltons, kDa). (Right panel) Western blot analysis
of 500 ng of CL and PE with a custom anti-human ORF2p monoclonal antibody. Molecular markers on the right, 10 to 250 kDa.
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ase (EN) domain [21], a reverse transcriptase (RT) domain
[22], and a C-terminal domain [23] with putative RNA
binding activity [24]. Human and mouse L1 ORF2 pro-
teins exhibit a high degree of sequence homology and
conservation of function making findings in mouse model
systems biologically relevant to the replication cycle of the
human L1 [25,26]. Although much has been learned about
ORF2p function in vitro and in mammalian cells using
overexpressed tagged ORF2 proteins and polyclonal anti-
ORF2p antibodies [27-30], having a monoclonal antibody
that can detect the untagged human ORF2 protein would
be a useful molecular tool to study the requirements for
the human L1 ORF2p expression and activity. It would
also aid in advancing our appreciation of the ORF2p im-
pact on host genome stability and in understanding the
consequences of its activity to human health.
To satisfy the need for a continuous source of antibodies
to detect L1 ORF2p, we developed an anti-ORF2p mono-
clonal antibody capable of recognizing sequences withinthe endonuclease domain of the human ORF2 protein.
This monoclonal antibody is specific to the human ORF2p
and can detect the full-length ORF2 protein, as well as
truncated ORF2 proteins overexpressed in mammalian
cells. Using a recombinant human L1 endonuclease
purified from bacterial cells as a standard [31,32], we
determined the sensitivity of this monoclonal anti-human
ORF2p antibody. The unique location of the epitope,
encompassing a position required for the function of the
human endonuclease domain, allowed us to test the ability
of this monoclonal anti-ORF2p antibody to inhibit L1
endonuclease activity in vitro using a fluorescence-based
cleavage assay.
Results
Generation of monoclonal antibody against human L1
ORF2p endonuclease
A recombinant human protein containing an ORF2p EN
domain N-terminally fused to a His-tag was purified from
bacterial cells as previously described [31-33], subjected
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(Figure 1B, Coomassie panel, expected product of 29
kDa). The efficiency of purification was also confirmed
using antibodies against the His-tag fused to the N-
terminus of the ORF2p EN (Figure 1B, His-Tag panel).
This purified recombinant human EN protein was used
for the immunization of Balb/c mice to generate mo-
noclonal anti-ORF2p antibodies following a standard
immunization protocol (see Methods). This approach
resulted in a positive hybridoma clone which was used
to produce the purified anti-ORF2p monoclonal anti-
bodies. Western blot analysis using this custom ORF2p
monoclonal antibody detected a product of the expected
size in the clarified lysate and the final elution of the hu-
man EN protein used for inoculation (Figure 1B, ORF2
monoclonal panel).
Anti-ORF2p monoclonal antibody is specific to the ORF2
protein of human origin
We determined that our anti-ORF2p monoclonal anti-
body detects full-length ORF2p and ORF2p endonuclease
in total cell lysates from 293 cells transiently transfec-
ted with plasmids containing human codon-optimized
full-length ORF2 or the ORF2 endonuclease sequences
(Figure 2A, lane hORF2 and hEN). Because the endo-
nuclease domain of the L1 ORF2 protein is highly con-
served between the human and mouse ORF2 proteins,
we tested whether our antibody discriminates between
ORF2 proteins of human and mouse origin. Plasmids
encoding mouse codon-optimized full-length ORF2 or
ORF2 endonuclease sequences were transiently trans-
fected into 293 cells and total cellular lysates were ana-
lyzed by SDS-PAGE followed by immunoblotting with
the anti-ORF2p monoclonal antibody. This approach
determined that the anti-ORF2p monoclonal antibody
does not detect mouse ORF2 or EN proteins (mORF2p
and mENp, respectively) even though it detected both
human ENp and ORF2p (Figure 2A, monoclonal Ab
panel). The mouse ENp and ORF2p were detected when
Western blot analysis was performed with polyclonal
antibodies raised against the endonuclease domain of the
mouse ORF2p [28] (Figure 2B, mouse Ab panel) confir-
ming that the proteins are expressed under these transfec-
tion conditions.
Anti-ORF2p monoclonal antibody recognizes an epitope
which includes amino acid 205 of the human ORF2p
endonuclease
Many experimental approaches designed to analyze the
expression and function of ORF2p involve the use of
both functional and non-functional ORF2 proteins. The
most commonly used mutations, which abolish the acti-
vity of the ORF2p endonuclease, are D205A and H230A
[21,34]. Western blot analysis of total cellular lysates fromhuman and mouse cells transiently transfected with EN or
EN 205, 230 plasmids containing codon-optimized se-
quences producing functional or non-functional (D205A,
H230A double mutant) human endonucleases demons-
trated that the anti-ORF2p monoclonal antibody detects
the active, but not the mutated, endonuclease protein
(Figure 3A, monoclonal; Additional file 1: Figure S1,
monoclonal). Both proteins were detected using the poly-
clonal anti-ORF2p antibody [28] (Figure 3A; Additional
file 1: Figure S1).
To determine which EN mutation is responsible for the
loss of detection by our anti-ORF2p monoclonal antibody,
total cellular lysates from cells transiently transfected with
EN 205 and EN 230 plasmids expressing non-functional
endonucleases with D205A or H230A mutations were
used for Western blot analysis with the anti-ORF2p mo-
noclonal antibody (Figure 3B, monoclonal). This approach
demonstrated that the anti-ORF2p monoclonal antibody
detects ENp containing the H230A mutation, but not the
ENp with the D205A mutation (Figure 3B, monoclonal).
Both ENp mutants are readily detected with the anti-
ORF2p polyclonal antibody [27,28], demonstrating that
both proteins are produced under these transfection
conditions (Figure 3B, polyclonal). A similar result was
obtained when the monoclonal anti-ORF2p antibody was
used to detect transiently expressed functional (ORF2)
and non-functional (single and double mutants) full-
length human ORF2 proteins (ORF2 205, ORF2 230,
and ORF2 205,230, respectively) as well as truncated,
functional, and double mutant human ORF2 proteins
(ENz and ENRT) [28] (Figure 4A–E, ORF2, ENz, and
ENRT). The anti-ORF2p monoclonal antibody specifi-
cally detected functional, but not the non-functional
ENz, ENRT, and ORF2 proteins containing the D205A
and H230A mutations, even though all of these proteins
were produced in these cells as confirmed by Western
blot analysis using polyclonal anti-ORF2p antibodies
(Figure 4D,E). These results support that the epitope
recognized by the anti-ORF2p monoclonal antibody
includes amino acid 205 of the human ORF2p endonu-
clease domain.
Sensitivity of the anti-ORF2p monoclonal antibody
The advent of L1 expression plasmids containing codon-
optimized sequences greatly facilitated our ability to de-
tect L1-encoded proteins in transfected mammalian cells
[35,36]. However, it remains important to study L1
proteins generated from wild-type L1 sequences and to
understand the difference in expression levels between
proteins generated from codon-optimized and wild-type
L1 sequences. As with the wild-type full-length L1 and
ORF2 expression plasmids, codon-optimized full-length
L1 expression plasmids produce much less ORF2 protein
than those containing a codon-optimized ORF2 sequence
Figure 2 Analysis of specificity of the custom anti-human ORF2p monoclonal antibody in human cells. (A) Western blot analysis of
mouse and human ORF2 (predicted size 150 and 149 kDa, respectively) and EN (predicted size 30 and 26 kDa, respectively) proteins generated
from expression plasmids containing codon-optimized human ORF2 (hORF2), a codon-optimized sequence corresponding to the human ORF2
endonuclease fragment (hEN), codon-optimized mouse ORF2 (mORF2), and a codon-optimized sequence corresponding to the mouse ORF2
endonuclease fragment (mEN) transiently transfected in 293 cells. Custom anti-human ORF2p monoclonal antibody specifically detects proteins of
human origin. (B) Western blot analysis of the same samples as in A was performed with custom anti-mouse ORF2p polyclonal antibodies which
specifically detect proteins of mouse origin. Control lane indicates cells transiently transfected with an empty vector. GAPDH is used as a loading
control; 15 to 150 kDa on the right indicate positions of molecular markers.
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clonal antibody detected different levels of ORF2p in cells
transfected under the same conditions with L1 expression
plasmids containing wild-type or codon-optimized se-
quences [6,36] (Figure 5). Transient transfection of 293
cells with plasmids containing codon-optimized ORF2 or
full-length wild-type L1 sequences produced the highestand the lowest levels of ORF2 protein, respectively. Trans-
fection of increasing amounts of plasmids containing
codon-optimized or wild type full-length L1 sequences
demonstrated that detectable levels of ORF2p were ob-
served when 2 and 4 μg of the respective plasmids were
used. No signal consistent with detection of endogen-
ous ORF2p in 293, Ntera2, nor HeLa cells was observed
Figure 3 Analysis of expression of functional and non-
functional human ORF2 protein in human cells. (A) Western blot
analysis of proteins generated from expression plasmids containing
codon-optimized, functional ORF2 endonuclease sequence (EN) and
non-functional ORF2 endonuclease sequence transiently transfected
in HeLa cells. Western blot analysis is performed with anti-human
ORF2p monoclonal antibody (top), the previously described anti-
human ORF2p endonuclease polyclonal antibodies (middle), and
GAPDH antibodies (bottom). The non-functional ORF2 endonuclease
sequence (EN 205, 230) has mutations resulting in expression of
inactive ENp with D205A and H230A mutations. (B) The same
experiment and analysis as in A, but using 293 cells. Western blot
analysis of codon-optimized, non-functional ORF2 endonuclease
sequences containing single inactivating mutations D205A or
H230A (EN205 and EN 230, respectively) transiently transfected in
293 cells with anti-human ORF2 monoclonal antibody (top) or
previously described anti-human ORF2p endonuclease polyclonal
antibodies (middle). Expected EN protein size is 26 kDa. Control
lane indicates cells transiently transfected with an empty vector; 25
and 37 kDa on the right indicate positions of molecular markers.
Sokolowski et al. Mobile DNA 2014, 5:29 Page 5 of 13
http://www.mobilednajournal.com/content/5/1/29(Additional file 2: Figure S2). Using the recombinant
human endonuclease purified from bacterial cells as a
standard, we determined that 27.6 μg of our anti-ORF2p
monoclonal antibody is able to detect 10 ng (2.2 × 1017
molecules) of the purified hEN under these blotting
conditions (Figure 6A). Based on the standard curve ge-
nerated by Western blot analysis of the recombinant
human EN purified from bacterial cells, we determined
that transfection of expression plasmids containing
codon-optimized human L1 sequences produce 5 to 6times more endonuclease protein than that observed from
cells transfected with equivalent amounts of plasmids con-
taining wild-type sequences (Figure 6, ENwt and ENco).Monoclonal anti-ORF2p antibody inhibits L1 endonuclease
activity in an in vitro endonuclease cleavage assay
The unique epitope location within the L1 EN as well as
the antibody’s ability to detect natively folded ORF2p
endonuclease purified from bacterial cells (Additional
file 3: Figure S3) open a possibility that the monoclonal
antibody may inhibit L1 endonuclease activity. For this
purpose, a previously reported in vitro endonuclease clea-
vage assay was used to measure L1 EN activity [31,32].
Figure 7A shows a schematic of the DNA products ex-
pected to be observed upon cleavage of the substrate
DNA by the L1 EN at the L1 EN site present in the tem-
plate DNA sequence. Figure 7B demonstrates detection of
the expected cleavage products resolved by PAGE when
a bacterially purified, functional human L1 EN protein
is present in the reaction. The addition of increasing
amounts of the monoclonal anti-ORF2p antibody re-
sulted in about 25% reduction of the cleaved products
(Figure 7B). This effect was not observed when an unre-
lated, anti-ORF1p antibody was included in the reaction
(Figure 7C). A similar in vitro endonuclease cleavage assay
using a functionally-related recombinant human apurinic/
apyrimidinic endonuclease 1 (APE 1), which shares se-
quence homology with the L1-encoded endonuclease, was
used to test the specificity of this effect. We observed no
change in the APE 1 activity upon the addition of the
highest amount of the L1 EN-specific antibody (200 nM;
Additional file 4: Figure S4).Discussion
L1 is responsible for all of the retrotransposon-induced
genomic instability in the human genome, as it is the
only active source of the functional ORF1 and ORF2
proteins required for mobilization of LINEs, SINEs, and
SVA elements [37-42]. L1 expression and retrotransposi-
tion are suppressed by many diverse cellular pathways in
order to minimize the genomic damage inflicted by L1
activity [20,43-50]. L1 encodes an ORF2 protein with
several identified functions essential for the retrotran-
sposition process. These include the endonuclease [21]
and reverse transcriptase [22] activities, and a putative
RNA binding domain within the C-terminus of the
protein [24]. Studies geared toward understanding the
biological relevance of this multifunctional protein and
its effect on human health necessitate manipulations
involving changes in protein sequence as well as
characterization of the expression of resulting ORF2p
variants in vitro, in cultured cells, and in vivo. To sat-
isfy this requirement, polyclonal antibodies against the
Figure 4 Analysis of expression of functional and non-functional full-length and truncated human ORF2 proteins in human cells.
(A) Schematic of L1 ORF2 protein. The following ORF2p domains are listed: Endonuclease domain (EN), Z domain (Z), Reverse Transcriptase
domain (RT), and the Cysteine-Rich domain (Cys). Amino acid boundaries of each domain are listed. (B) Western blot analysis of the full-length
and truncated ORF2 proteins generated from expression plasmids containing codon-optimized, functional full-length ORF2 (ORF2) and C-terminally
truncated ORF2 sequences transiently transfected in 293 cells with monoclonal antibody. Control lane indicates cells transiently transfected with an
empty vector. (C) Western blot analysis of proteins with two inactivating mutations are labeled as 205, 230, single mutants are labeled as 205 or 230
generated from expression plasmids containing codon-optimized, mutant of the constructs described in A transiently transfected in 293 cells with
monoclonal antibody. Constructs containing two inactivating mutations are labeled as 205, 230, single mutants are labeled as 205 or 230. (D) Western
blot analysis of the same samples described in A with polyclonal anti-ORF2p antibodies. (E) Western blot analysis of the same samples described in B
with anti-human ORF2p polyclonal antibodies. GAPDH is used as a loading control; 50 to 150 kDa and 37 kDa on the right indicate molecular markers.
Arrows denote bands of expected molecular weights for each construct listed.
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Figure 5 Analysis of ORF2p generated from a functional wild-type and a functional codon-optimized full-length L1 expression plasmids
in 293 cells. (Top) Western blot analysis of ORF2p generated from expression plasmids containing a full-length wild-type L1 (L1wt), a full-length
codon-optimized L1 (L1co), or a codon-optimized ORF2 transiently transfected in 293 cells with supernatant collected from cultured hybridoma cells
producing anti-ORF2 antibody; 293 cells were transfected with 1, 2, or 4 μg of the L1wt or L1co expression plasmids or 2 μg of the ORF2 expression
plasmid and total protein was harvested 24 hours after transfection. Control lane indicates cells transiently transfected with an empty vector.
Positions of molecular markers are indicated on the right as 100 or 150 kDa. (Bottom) The same experiment and analysis as in (top), but using
secondary antibodies only. Positions of molecular markers are indicated on the right as 100 or 150 kDa. Total amount of 293 cell lysate loaded
is in μg.
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previously reported [27-29].
We have developed a custom monoclonal antibody to
the human L1 ORF2p endonuclease domain that will
help to advance future studies involving ORF2p expres-
sion and function. The monoclonal nature of the anti-
body provides a continuous source of antibody, thereby
eliminating the inherent issue with reproducibility com-
monly associated with different batches of polyclonal
antibodies raised against the same antigen. Similar to
previously reported polyclonal antibodies [27], our mo-
noclonal anti-ORF2p antibody detects untagged ORF2
protein expressed from the plasmids containing full-
length wild-type or codon-optimized L1 elements. This
characteristic is beneficial because the addition of
different tags can interfere with L1 protein function or
subcellular localization [20,51]. Using bacterially pu-
rified endonuclease protein, we generated a standard
curve that allowed us to determine the sensitivity of
our monoclonal antibodies, which is about 10 ng of the
purified protein under the described detection condi-
tions (Figure 6). Consistent with the previous reports,
we confirmed that codon-optimization of the human
L1 ORF2 sequence results in a 5- to 6-fold increase in
EN protein production [35,36]. As we were unable to
detect endogenously expressed L1 ORF2p in HeLa and
293 cells, our calculations suggest that endogenous levels
of L1 ORF2p expression are less than 10 ng of protein per
10 μg of cellular lysate.
Additionally, we determined that our antibody specific-
ally recognizes human, but not mouse, ORF2 protein des-
pite the relatively strong sequence conservation betweenthe endonuclease domains of the two proteins (Additional
file 5: Figure S5) [36,52]. This feature is useful for studies
involving mouse cells and human ORF2 protein. We also
ascertained that the epitope recognized by the monoclonal
anti-ORF2p antibody includes amino acid 205 of the
human ORF2p endonuclease domain. This amino acid
is required for the ORF2p endonuclease activity and
is therefore necessary for L1-driven retrotransposition
(Figures 3 and 4). As a result, our antibody exhibits
some bias toward detection of the ORF2 proteins
containing a functional endonuclease domain at least
relative to the status of amino acid 205. Additionally,
an alignment of the consensus L1PA1-PA8 ORF2p se-
quences [52] demonstrated that L1PA3 to 5 have the same
sequence as L1PA1, whereas L1PA2, 6, and 7 have one
substitution in the core region surrounding amino acid
205 (200-210aa) (Additional file 5: Figure S5). The same
analysis identified that L1PA8 varies by two amino acids
from the L1PA1 sequence.
This discovery opens up the possibility that our mo-
noclonal antibody may inhibit human L1 endonuclease
activity. Suppression of L1 retrotransposition by HIV re-
verse transcriptase inhibitors has been previously reported
[53,54], generating an interest in developing L1-specific
inhibitors with the potential to suppress L1-associated
damage in vivo. While the use of such RT inhibitors serves
as a helpful tool to study the L1 replication cycle, these in-
hibitors are not specific to L1 as they are also expected to
suppress telomerase RT [55]. Furthermore, they have sig-
nificant side effects in humans [56] and it is not known
whether the inhibition of the RT also prevents damage
from the L1 endonuclease-induced DNA double-stranded
Figure 6 Analysis of sensitivity of the custom anti-human ORF2p monoclonal antibody. (A) Western blot analysis of protein generated
from expression plasmids containing wild-type ORF2 endonuclease sequence (ENwt), codon-optimized ORF2 endonuclease sequence (ENco), and
codon-optimized ORF2 sequence (ORF2) transiently transfected in 293 cells with our monoclonal antibody; 5 or 10 μg of the whole cell lysate
was used for analysis as indicated. Control lane indicates cells transiently transfected with an empty vector. Bacterially purified endonuclease was
loaded at 0 (empty, buffer only), 10, 20, and 40 ng. GAPDH is used as a loading control; 15 to 150 kDa on the right indicate positions of molecular
markers. Arrows denote bands of expected sizes for each protein. (B) A standard curve was generated using the quantitation of the increasing
amounts of the bacterially purified endonuclease shown in A. Signals detected for ORF2co, ENco, and ENwt are plotted and labeled with the
respective names of the proteins.
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attractive approach in order to suppress most, if not all, of
the L1-induced damage. The development of either
chemical or antibody-based inhibitors are the two of the
main approaches generally used for the suppression of
enzymatic activities. In addition to the effective inhibition
of enzyme activity, efficient delivery, stability, and lack of
toxicity are common goals for both types of inhibitors
[57,58]. The specificity of inhibition is a potential chal-
lenge with the development of L1 endonuclease inhibitors
because this endonuclease is related to the human APE1,
which is involved in the repair of DNA damage by thebase excision repair pathway [59]. Using a fluorescence-
based in vitro cleavage assay, we demonstrated that our
monoclonal anti-ORF2p antibody can reduce L1 en-
donuclease activity by about 25% without any inhibi-
tory effect on the in vitro activity of the human APE1
(Additional file 4: Figure S4). While it is not known yet
whether the antibody is able to inhibit L1 endonuclease
activity in the context of the full-length ORF2 protein
or in the cellular environment, these results provide the
first proof of principle that an antibody specific to
amino acid 205 of the L1 endonuclease can reduce the
activity of the enzyme.
Figure 7 Monoclonal anti-ORF2p antibody inhibits L1 endonuclease activity in an in vitro endonuclease cleavage assay. (A) Schematic
of in vitro endonuclease cleavage assay. Double-stranded DNA containing L1 ORF2 endonuclease consensus target sequence with 5′ tagged with
fluorophore. L1 ORF2 endonuclease is added, DNA is cleaved releasing the fluorphore, which can be quantitated. (B) (Top) SDS-PAGE analysis of
the products resulting from the in vitro endonuclease assay with or without the addition of the monoclonal anti-ORF2 antibody (0, 100, 150,
200 nM). Antibody (ORF2) denotes the addition of the monoclonal anti-ORF2 antibody, control indicates the addition of the same volume of the
buffer used for the reactions containing monoclonal anti-ORF2p antibody, and L1 EN denotes bacterially purified human ORF2 endonuclease.
(Bottom) Quantitation of the results of the in vitro endonuclease cleavage assay in A (see Methods). Results were normalized to 0 nM control
(n = 3). (C) Same experimental approach as in B, but anti-hORF1p antibody was added to the in vitro endonuclease cleavage assay.
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Our data demonstrate that this anti-ORF2p monoclonal
antibody will be a useful tool for studies involving human
L1 because it is specific to human ORF2p. The anti-
ORF2p monoclonal antibody detects ORF2 protein gener-
ated from the ORF2 expression plasmid as well as both
codon-optimized and wild-type full-length L1 expression
plasmids transiently transfected into human cells. Our
data also establish a rationale for the development of
antibody-based inhibitors of L1-induced damage.
Methods
Cells
FLP-In™-293 (Invitrogen) cells were cultured in HyClone
Dulbecco’s modified Eagle’s medium with 10% fetal bovine
serum (Invitrogen) and maintained under 6% CO2 at 37°C.
HeLa (ATCC CCL2), NIH-3T3 (ATCC CRL-1658), and
Ntera2 (ATCC CRL-1973) cells were maintained as
previously described [50].
Transfections
Western blot: 293 cells were seeded at 1.5 × 106 cells per
T25 flask and transfected 16 to 18 hours later with 2 μgof the human or mouse ORF2 or EN expression plas-
mids [28], or 1, 2, or 4 μg of codon-optimized L1Pa1
[36] (L1co) or wild-type L1.3 (L1wt) [6,36]. Plus reagent
(6 μL) and Lipofectamine (8 μL) (Invitrogen) were used
for each ORF2 or EN transfection reaction in serum-free
media; 12 μL of Plus reagent and 24 μL of Lipofectamine
were used for each transfection reaction with L1co or
L1wt in serum-free media. Transfections with maximum
amount of the empty pCDNA plasmid were used as con-
trols. After 3 hours, serum-free media was replaced with
serum-containing media, and the cells were harvested at
24 hours after transfection unless otherwise noted in the
figure. HeLa and NIH-3T3 cells were seeded at 2 × 106
and 2.5 × 106 cells per T75 flask, respectively, and trans-
fected as previously described using 6 μg of plasmid
[51], 12 μL of Plus reagent, and 18 μL or 24 μL of
Lipofectamine, respectively, in serum-free media.
Total protein extraction
Total protein was extracted as previously described
[28,51] using phosphate buffered saline (PBS; 137 mM
NaCl (Sigma S9888), 2.7 mM KCl (Sigma P4505), 10 mM
Na2HPO4 (Sigma S3264), 2 mM KH2PO4 (Sigma P9791),
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ED), and 0.02% sodium azide (Sigma S2002). Lysis buffer
was supplemented with phosphatase inhibitors 2 and 3
(Sigma P5726 and P0044, respectively) and Halt Protease
inhibitors at 10 μL/mL each. The samples were subjected
to two freeze (−80°C)/thaw (25°C) cycles. The samples
were sonicated three times for 10 seconds at 12 watts
RMS using a 3 mm wide QSonica Microson homogenizer
with Microson ultra sonic disruptor XL2000 (Misonix).
The protein concentration of each sample was determined
using 595 nm wavelength OD values against a bovine
serum albumin standard.
Western blot analysis
A 10 to 20 μg of total protein were combined with 2×
Laemmli buffer and 1.6 μL (14.3 M) β-mercaptoethanol
and boiled for 5 minutes prior to fractionation on Tris
Acetate 3-8% Midi gels, Bis Tris 4 to 12% Midi gels
(Invitrogen), and transferred onto nitrocellulose mem-
branes (iBlot System; Invitrogen). Membranes containing
fractionated protein samples were blocked for 1 hour in
PBS-Tween containing 5% milk and incubated with a
1:250 dilution of custom polyclonal antibodies against
the mouse ORF2p endonuclease [28], a 1:500 dilution of
custom polyclonal antibodies against the human ORF2p
endonuclease [27,28] antibodies, or a 1:250 dilution of
custom monoclonal antibodies against the human ORF2p
endonuclease overnight at 4°C. Detection was carried out
using horseradish peroxidase (HRP)-conjugated secondary
antibodies, either HRP-donkey anti-goat (Santa Cruz;
sc-2020), HRP-donkey anti-rabbit (Santa Cruz; sc-2317),
or HRP-goat anti-mouse (Santa Cruz; sc-2031) at a
1:5,000 dilution in 3% milk in PBS-Tween for 1 hour.
A 1:5000 dilution of GAPDH antibodies (Santa Cruz
sc-25778) was used as an equal loading control. A HRP
conjugated monoclonal antibody against the 6× HIS tag
(Pierce MA1-21315-HRP) was used at a 1:2000 dilution.
All Western blots were developed using Clarity™ Western
ECL Substrate (Bio-Rad, Cat. #170-5061).
For SDS Tris Glycine gels (Figure 5; Additional file 4:
Figure S4), 3 to 20 μg of total protein were combined with
2× Tris Glycine SDS sample buffer and 1.6 μL (14.3 M)
β-mercaptoethanol and boiled for 5 minutes prior to
fractionation on Tris Glycine 4% Mini gels with Tris
Glycine SDS running buffer (Invitrogen) and transfer
onto nitrocellulose membranes. Membranes containing
fractionated proteins were blocked for 1 hour in PBS-
Tween containing 5% milk at room temperature. The
membranes were then incubated overnight at 4°C with
1 mL of Ab-containing hybridoma supernatant in a
blocking mixture containing 4 mL of media collected
from NIH-3T3 cells cultured for 24 hours and 15 mL
of 3% milk in PBS-Tween. Detection was carried out
using HRP-conjugated secondary antibodies HRP-goatanti-mouse (Santa Cruz; sc-2031) at a 1:5,000 dilution
in 3% milk in PBS-Tween for 1 hour. All Western blots
were developed using Clarity™ Western ECL Substrate
(Bio-Rad, Cat. #170-5061).
For Tris Glycine Native gel (Additional file 2: Figure S2),
100 ng of bacterially purified human ORF2p endonuclease
was combined with 2× Native Tris Glycine sample buffer
along with 5% GelCode Blue Stain Reagent (Thermo
Scientific, Prod # 24592) and fractionated on a Tris
Glycine 4 to 12% gel with Tris Glycine Native running
buffer (Invitrogen). Fractionated proteins were transferred
onto a nitrocellulose membrane. Membranes containing
fractionated proteins were blocked for 1 hour in PBS-
Tween containing 5% milk at room temperature. The
membranes were then incubated overnight at 4°C with
1 mL of Ab-containing hybridoma supernatant in a
blocking mixture containing 4 mL of media collected
from NIH-3T3 cells cultured for 24 hours and 15 mL
of 3% milk in PBS-Tween. Detection was carried out
using HRP-conjugated secondary antibodies HRP-goat
anti-mouse (Santa Cruz; sc-2031) at a 1:5,000 dilution
in 3% milk in PBS-Tween for 1 hour. All Western blots
were developed using Clarity™ Western ECL Substrate
(Bio-Rad, Cat. #170-5061).
Plasmids
All endonuclease constructs used in this study have been
previously described [28], as well as ORF2 constructs
[28] and L1PA1 (codon-optimized full-length L1) [36].
‘L1wt’ is JM101/L1.3 no tag [6].
ORF2p endonuclease purification
A human ORF2 endonuclease was expressed in bacteria
and the EN protein was purified as previously described
[31-33].
Monoclonal antibody production
hORF2p endonuclease was bacterially purified as pre-
viously described [31,32]. This purified human ORF2
endonuclease protein was used for immunization of 6
Balb/c mice to generate monoclonal anti-ORF2p an-
tibodies following a standard immunization protocol.
Briefly, three sequential immunizations (with 2 week
intervals between the injections) with antigen, (purified
ORF2p endonuclease diluted in saline) in complete
Freund’s Adjuvant for the first injection and incomplete
Freund’s Adjuvant for the second and third injection,
injected intraperitoneally, were performed. The fourth
and final immunization was done using the antigen in
saline. Mice were bled and tested using ELISA to de-
termine which mouse to use as the source of B-cells
for hybridoma production. Electrofusion was performed
between B-cells harvested from the spleen and mye-
loma cells to produce hybridomas. Resulting hybridoma
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positive clones. The final stock of antibody was obtained
by protein-G affinity column purification. The antibodies
were stored in a PBS with 0.02% W/V sodium azide
storage solution. The affinity purified hORF2p monoclonal
antibodies were used for subsequent testing.
The LINE-1 EN cleavage assay
The LINE-1 EN was expressed and purified as described
previously [31,32]. The LINE1 EN cleavage assay was
performed using 200 nM purified LINE1 EN, 100 nM of
a duplexed oligonucleotide containing LINE-1 EN
target site. The reaction buffer contained 20 mM Hepes
(pH 6.5), 150 mM NaCl, 1 mM MgCl2, 1 mM dithio-
threotol (DTT), 1% dimethyl sulfoxide (DMSO), 0.1%
triton, and 0.01% sodium azide.
The effect of the monoclonal anti-ORF2p antibody on
LINE1 EN activity was tested using three concentrations:
100 nM, 150 nM, and 200 nM. The antibody was diluted
into the above described reaction buffer just prior to
use. The same was done for the anti-hORF1p antibody
[51]. A buffer control was used for background subtrac-
tion, in which the same volume of buffer alone as the
volume of buffer containing antibody was added to the
reactions. The LINE-1 EN and APE1 EN cleavage reac-
tions were carried out at 37°C for 30 minutes. The reac-
tions were stopped by quenching on ice and the addition
of stop solution: 1× Tris borate EDTA buffer, 80% form-
amide, 0.01 mM EDTA, and xylene cyanol. The samples
were run on 18% denaturing acrylamide gels and were
analyzed using the Typhoon imager (GE Lifesciences).
Fluorescense intensity (FI) was measured using Image
Quant software (GE Lifesciences) and graphed using
Prism software (GraphPad software, LLC). The percent in-
hibition of each reaction was determined using the follow-
ing equation: % Inh = 100 × (1 − (FIAntibody − FIBufferControl)/
(FIL1/APE1 EN − FIBuffer Control)).
The APE1 EN cleavage assay
The purified APE1 EN was purchased from New England
Biolabs. The assay was performed using 0.01 and 0.1 units
of enzyme and 200 nM of duplexed oligonucleotide con-
taining an abasic site. The sequence of the oligonucleotide
was based upon previously published work [59]. The reac-
tion buffer contained 50 mM potassium acetate 20 mM
tris-acetate, 10 mM magnesium acetate, 1 mM DTT, 1%
DMSO, 0.1% triton, and 0.01% sodium azide.
Annealing oligonucleotides
All oligonucleotides were purchased from Integrated
DNA Technologies. The oligonucleotides used in the as-
says were annealed by adding equivalent amounts of each
complimentary nucleotide in annealing buffer (50 mM
Hepes (pH 7.5) and 100 mM NaCl). The samples wereincubated in boiling water for 5 minutes and slow
cooled for 1 hour in the dark. The sequence for the
LINE1 EN oligonucleotides used in the assay are as
follows: 5′/AlexaFluor488/CCTTTTTTTTTAACCGC3′
and 5′GCGGTTAAAAAAAAAGG3′. The sequence for
the APE1 EN oligonucleotides used in the assay are as fol-
lows: 5′/AlexaFluor488/GCCCCC_GGGGACGTACGATA
TCCCGCTCC3′ (where “_” represents an abasic site) and
5′GGAGCGGGATATCGTACGTCCCCCGGGGGC3′.
Alignment of human and mouse ORF2p endonuclease
domains
Human L1PA family consensus sequences [52] and L1
Spa [60] ORF2 sequence were converted to amino acid
sequences and aligned using DNASTAR MegAlign
program through the Clustal V method utilizing a gap
penalty of ‘10’ and a gap penalty length of ‘10’.
Calculation of the number of protein molecules
The molecular weight of all proteins was calculated
based on their amino acid composition using EditSeq
software. The number of molecules detected by mono-
clonal anti-ORF2p antibody was calculated using the
following formula:
Xmolecules ¼ ½Mass gð Þ=Molecular weight of a
specific protein g=molð Þ
 6:022 1023 mol‐1 
Additional files
Additional file 1: Figure S1. Analysis of expression of functional and
non-functional human ORF2 endonuclease domains in NIH-3T3 cells.
Western blot analysis of proteins generated from expression plasmids
containing codon-optimized functional (EN) and non-functional
(EN 205,230) ORF2 endonuclease sequences transiently transfected
in NIH-3T3 cells with anti-human ORF2p monoclonal antibody (top),
anti-human ORF2p polyclonal antibodies (middle), or GAPDH (bottom).
Control lane indicates cells transiently transfected with an empty vector;
25 and 37 kDa are molecular markers.
Additional file 2: Figure S2. Analysis of endogenous ORF2p in
different cell lines. (Top) Western blot analysis of total cell lysate from
the following cell lines: NIH-3T3, 293, Ntera2, and HeLa using hybridoma
supernatant. Protein lysate from 293 cells transiently transfected with an
expression plasmid containing codon-optimized ORF2 was used as a
positive control for ORF2p expression (third lane). Control lane indicates
293 cells transiently transfected with an empty vector. Positions of
molecular markers are indicated on the right as 100 or 150 kDa. (Bottom)
The same experiment and analysis as in (top), but using secondary
antibodies only. Positions of molecular markers are indicated on the right
as 100 or 150 kDa. Total amount of cell lysate loaded is in micrograms (μg).
Additional file 3: Figure S3. Analysis of functional ORF2p
endonuclease in native conformation. Western blot analysis of the
bacterially purified ORF2p endonuclease (EN) fractionated under native
conditions using hybridoma supernatant. Buffer lane indicates storage
buffer used for purified ORF2p endonuclease.
Additional file 4: Figure S4. Monoclonal anti-ORF2p antibody does not
inhibit the APE1 endonuclease activity in vitro. (Top) SDS-PAGE analysis
of in vitro APE1 endonuclease cleavage assay using monoclonal anti-ORF2
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anti-ORF2p antibody, control indicates the addition of the same volume of
the buffer used for the reactions containing monoclonal anti-ORF2 antibody,
and APE1 denotes bacterially purified human APE1 endonuclease; 0.1 and
0.01 units of APE1 were tested. (Bottom) Quantitation of the results of the
in vitro APE1 endonuclease cleavage assay in A. Results were normalized to
0 nM control (n = 3). Equation used to determine percent (%) inhibition is
listed in the methods section.
Additional file 5: Figure S5. Analysis of ORF2p endonuclease
conservation in human and mouse. Alignment of ORF2p endonucleases
of L1Pa families in humans and the ORF2p endonuclease domain of
mouse L1 Spa. Black arrow indicates area of the epitope of anti-ORF2p
monoclonal antibody.
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